Obstetrics and Gynecology International
Volume 2009 (2009), Article ID 359457, 8 pages
doi:10.1155/2009/359457
Research Article

The HPV Cellular Transactivator Brn-3a Can Be Used to Predict Cervical Adenocarcinoma and Squamous Carcinoma Precancer Lesions in the Developed and Developing Worlds

Daniel Ndisang,1 Felipe Lorenzato,2 Michael Sindos,1 Ashfaq Khan,1,3 Albert Singer,3 and David S. Latchman1,4

1Medical Molecular Biology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK
2Instituto Materno Infantil de Pernambuco (IMIP), Rua dos coelhos, 300 Boa Vista Recife 1393, Pernambuco, Brazil
3Department of Women's and Children's Health, The Whittington Hospital, Highgate Hill, London N19 5NF, UK
4Birkbeck, University of London, Malet Street, London WC1E 7HX, UK

Received 4 September 2009; Revised 27 December 2009; Accepted 29 December 2009

Academic Editor: Michelle A. Williams

Copyright © 2009 Daniel Ndisang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Human papillomavirus and cervical cancer,” WHO Report, WHO, http://www.who.int/vaccine_research/diseases/hpv/en.
  2. D. M. Parkin, P. Pisani, and J. Ferlay, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 49, no. 1, pp. 33–64, 1999.
  3. M. Durst, L. Gissmann, H. Ikenberg, and H. Zur Hausen, “A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 12 I, pp. 3812–3815, 1983.
  4. F. X. Bosch, M. M. Manos, N. Munoz, et al., “Prevalence of human papillomavirus in cervical cancer: a worldwide perspective,” Journal of the National Cancer Institute, vol. 87, no. 11, pp. 796–802, 1995.
  5. E. C. Pirog, B. Kleter, S. Olgac, et al., “Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma,” American Journal of Pathology, vol. 157, no. 4, pp. 1055–1062, 2000.
  6. X. Castellsagué, M. Díaz, S. de Sanjosé, et al., “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention,” Journal of the National Cancer Institute, vol. 98, no. 5, pp. 303–315, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. A. Hildesheim and A. B. de González, “Etiology and prevention of cervical adenocarcinomas,” Journal of the National Cancer Institute, vol. 98, no. 5, pp. 292–293, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. T. Zheng, T. R. Holford, Z. Ma, et al., “The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon,” International Journal of Epidemiology, vol. 25, no. 2, pp. 252–258, 1996. View at Publisher · View at Google Scholar
  9. J. Brown, R. Broaddus, M. Koeller, T. W. Burke, D. M. Gershenson, and D. C. Bodurka, “Sarcomatoid carcinoma of the cervix,” Gynecologic Oncology, vol. 90, no. 1, pp. 23–28, 2003. View at Publisher · View at Google Scholar
  10. C.-P. Lin, C.-L. Ho, M.-R. Shen, L.-H. Huang, and C.-Y. Chou, “Evidence of human papillomavirus infection, enhanced phosphorylation of retinoblastoma protein, and decreased apoptosis in sarcomatoid squamous cell carcinoma of uterine cervix,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 336–340, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. L. C. Pang, “Sarcomatoid squamous cell carcinoma of the uterus,” International Journal of Gynecological Pathology, vol. 17, pp. 174–177, 1998.
  12. J. Gregg, “Mixed blessings: cervical cancer screening in Recife, Brazil,” Medical Anthropology, vol. 19, no. 1, pp. 41–63, 2000.
  13. G. Azevedo and S. Mendonça, “Cancer in the female population in Brazil,” Revista de Saude Publica, vol. 27, no. 1, pp. 68–75, 1993.
  14. T. Zheng, T. R. Holford, Z. Ma, et al., “The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon,” International Journal of Epidemiology, vol. 25, no. 2, pp. 252–258, 1996. View at Publisher · View at Google Scholar
  15. F. R. Lorenzato, A. Singer, L. Ho, et al., “Human papillomavirus detection for cervical cancer prevention with polymerase chain reaction in self-collected samples,” American Journal of Obstetrics and Gynecology, vol. 186, no. 5, pp. 962–968, 2002.
  16. F. Lorenzato, L. Ho, G. Terry, et al., “The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil),” International Journal of Gynecological Cancer, vol. 10, no. 2, pp. 143–150, 2000. View at Publisher · View at Google Scholar
  17. Y. F. Matos, H. L. F. F. Costa, and A. E. Faundes, “Prevalence of cervical squamous intraepithelial lesions in women with HIV,” International Journal of Gynecology and Obstetrics, vol. 83, no. 1, pp. 63–64, 2003. View at Publisher · View at Google Scholar
  18. D. Ndisang, F. Lorenzato, M. Sindos, A. Singer, and D. S. Latchman, “Detection of cervical abnormalities in a developing country using measurement of Brn-3a in cervical smears,” Gynecologic Oncology, vol. 100, no. 1, pp. 89–94, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. C. B. J. Woodman, S. Collins, H. Winter, et al., “Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study,” The Lancet, vol. 357, no. 9271, pp. 1831–1836, 2001. View at Publisher · View at Google Scholar · View at PubMed
  20. Human Papillomaviruses, vol. 64 of IARC Monographs on the Evaluation of Carcinogenic Risks to Human, International Agency for Research in Cancer, Lyon, France, 1995.
  21. T. P. Cripe, T. H. Haugen, J. P. Turk, et al., “Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis,” The EMBO Journal, vol. 6, no. 12, pp. 3745–3753, 1987.
  22. B. Gloss, H. U. Bernard, K. Seedorf, and G. Klock, “The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones,” The EMBO Journal, vol. 6, no. 12, pp. 3735–3743, 1987.
  23. P. J. Morris, C. L. Dent, C. J. Ring, and D. S. Latchman, “The octamer binding site in the HPV16 regulatory region produces opposite effects on gene expression in cervical and non-cervical cells,” Nucleic Acids Research, vol. 21, no. 4, pp. 1019–1023, 1993.
  24. C. L. Dent, G. A. McIndoe, and D. S. Latchman, “The constitutively expressed octamer binding protein OTF-1 and a novel octamer binding protein expressed specifically in cervical cells bind to an octamer-related sequence in the human papillomavirus 16 enhancer,” Nucleic Acids Research, vol. 19, no. 16, pp. 4531–4535, 1991.
  25. K. A. Lillycrop, V. S. Budrahan, N. D. Lakin, et al., “A novel POU family transcription factor is closely related to Brn-3 but has a distinct expression pattern in neuronal cells,” Nucleic Acids Research, vol. 20, no. 19, pp. 5093–5096, 1992.
  26. P. J. Morris, T. Theil, C. J. A. Ring, K. A. Lillycrop, T. Moroy, and D. S. Latchman, “The opposite and antagonistic effects of the closely related POU family transcription factors Brn-3a and Brn-3b on the activity of a target promoter are dependent on differences in the POU domain,” Molecular and Cellular Biology, vol. 14, no. 10, pp. 6907–6914, 1994.
  27. D. Ndisang, D. J. Faulkes, D. Gascoyne, et al., “Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a,” Oncogene, vol. 25, no. 1, pp. 51–60, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. D. Ndisang, V. Budhram-Mahadeo, and D. S. Latchman, “The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells,” Journal of Biological Chemistry, vol. 274, no. 40, pp. 28521–28527, 1999. View at Publisher · View at Google Scholar
  29. D. Ndisang, V. Budhram-Mahadeo, B. Pedley, and D. S. Latchman, “The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo,” Oncogene, vol. 20, no. 35, pp. 4899–4903, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. D. Ndisdang, P. J. Morris, C. Chapman, L. Ho, A. Singer, and D. S. Latchman, “The HPV-activating cellular transcription factor Brn-3a is overexpressed in CIN3 cervical lesions,” Journal of Clinical Investigation, vol. 101, no. 8, pp. 1687–1692, 1998.
  31. M. Sindos, D. Ndisang, N. Pisal, C. Chow, A. Singer, and D. S. Latchman, “Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia,” Gynecologic Oncology, vol. 90, no. 2, pp. 366–371, 2003. View at Publisher · View at Google Scholar
  32. M. Sindos, D. Ndisang, N. Pisal, et al., “Detection of cervical neoplasia using measurement of Brn-3a in cervical smears with persistent minor abnormality,” International Journal of Gynecological Cancer, vol. 13, no. 4, pp. 515–517, 2003. View at Publisher · View at Google Scholar
  33. D. Ndisang, V. Budhram-Mahadeo, A. Singer, and D. S. Latchman, “Widespread elevated expression of the human papilloma virus (HPV)-activating cellular transcription factor Brn-3a in the cervix of women with CIN3,” Clinical Science, vol. 98, no. 5, pp. 601–602, 2000.
  34. S. S. Raab, “Can glandular lesions be diagnosed pap smear cytology?” Diagnostic Cytopathology, vol. 23, no. 2, pp. 127–133, 2000. View at Publisher · View at Google Scholar
  35. D. S. Latchman, “Role of the Brn-3a and Brn-3b POU family of transcription factors in cancer,” Gene Therapy & Molecular Biology, vol. 8, pp. 343–350, 2004.
  36. D. Ndisang, F. Lorenzato, M. Sindos, K. Khan, A Singer, and D. Latchman, “The cellular transcription factor Brn-3a and the smoking related substance nicotine interact to regulate the activity of the HPV URR in the cervix,” Oncogene. In press.
  37. D. M. Harper, E. L. Franco, C. Wheeler, et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at PubMed